TRIANA Biomedicines
Louis Plamondon, Ph.D., currently serves as Executive Vice President and Head of Pharmaceutical Development at TRIANA Biomedicines since October 2024. Prior to this role, Plamondon held several prominent positions at LifeMine Therapeutics, Constellation, Vertex Pharmaceuticals, Karyopharm Therapeutics Inc., Tetraphase Pharmaceuticals, and Millennium Pharmaceuticals, where responsibilities included leading CMC activities, managing drug development processes, and overseeing teams in chemistry and pharmaceutical sciences. With a strong track record in developing small molecule drugs and substantial experience in cGMP manufacturing, Plamondon has contributed to significant advancements in oncology and microbiology. Educational qualifications include a Ph.D. in Organic Chemistry from Université de Montréal and postdoctoral research at Harvard University.
This person is not in any teams
This person is not in any offices
TRIANA Biomedicines
Triana Biomedicines is a developer of a molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high-resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas.